TVTX travere.com: Nilai bisnis marang pendapatan

The EV/Sales multiple history demonstrates the business value dynamics relative to its revenues, with 7151.68 reflecting the metric's most recent value. Travere Therapeutics (TVTX) is implementing vital nephropathy therapies that prevent dialysis. The integration of patient support service centers optimizes logistics and retains physicians. Growth is driven by Filspari sales in Europe and successes in treating FSGS.
TVTX (Retrophin): rincian analitis lan laporan miturut indikator

This indicator compares the total enterprise value (market capitalization plus net debt) with annual sales volume, allowing for an asset valuation independent of the debt load. The EV/Sales ratio trend reflects market expectations for the revenue scaling of Travere Therapeutics (TVTX), which is optimizing costs through the outsourcing of orphan drug development, directly impacting the company's fundamental attractiveness.